| Dr Patrick F Martinez, MD | |
|
4951 Business Park Blvd, Anchorage, AK 99503-7174 | |
| (907) 743-7200 | |
| Not Available |
| Full Name | Dr Patrick F Martinez |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 4951 Business Park Blvd, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518901321 | NPI | - | NPPES |
| 240392 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3534 (Alaska) | Primary |
| 207P00000X | Emergency Medicine | MD26613 (Oregon) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Kodiak Island Medical Ctr | Kodiak, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anchorage Neighborhood Health Center Inc | 0941107288 | 37 |
| Providence Health And Services Washington | 5799675120 | 15 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Rising food prices could force 64 million Asians into extreme poverty and damage the region's economic growth this year, according to a report released on Tuesday from the Asian Development Bank, Agence France-Presse reports.
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Mindfulness meditation is an increasingly popular treatment for anxiety, but testing its effectiveness in a convincing way has been difficult. Now a rigorously designed, NIH-sponsored clinical trial has found objective physiological evidence that mindfulness meditation combats anxiety.
› Verified 3 days ago
| Entity Name | Anchorage Neighborhood Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811170210 PECOS PAC ID: 0941107288 Enrollment ID: O20040227000941 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Rising food prices could force 64 million Asians into extreme poverty and damage the region's economic growth this year, according to a report released on Tuesday from the Asian Development Bank, Agence France-Presse reports.
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Mindfulness meditation is an increasingly popular treatment for anxiety, but testing its effectiveness in a convincing way has been difficult. Now a rigorously designed, NIH-sponsored clinical trial has found objective physiological evidence that mindfulness meditation combats anxiety.
› Verified 3 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952430902 PECOS PAC ID: 5799675120 Enrollment ID: O20040318000605 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Rising food prices could force 64 million Asians into extreme poverty and damage the region's economic growth this year, according to a report released on Tuesday from the Asian Development Bank, Agence France-Presse reports.
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Mindfulness meditation is an increasingly popular treatment for anxiety, but testing its effectiveness in a convincing way has been difficult. Now a rigorously designed, NIH-sponsored clinical trial has found objective physiological evidence that mindfulness meditation combats anxiety.
› Verified 3 days ago
| Entity Name | City Of Valdez |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427424282 PECOS PAC ID: 3577514694 Enrollment ID: O20160406001911 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Rising food prices could force 64 million Asians into extreme poverty and damage the region's economic growth this year, according to a report released on Tuesday from the Asian Development Bank, Agence France-Presse reports.
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Mindfulness meditation is an increasingly popular treatment for anxiety, but testing its effectiveness in a convincing way has been difficult. Now a rigorously designed, NIH-sponsored clinical trial has found objective physiological evidence that mindfulness meditation combats anxiety.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick F Martinez, MD 18627 Man O War Rd, Eagle River, AK 99577-8336 Ph: (907) 696-6312 | Dr Patrick F Martinez, MD 4951 Business Park Blvd, Anchorage, AK 99503-7174 Ph: (907) 743-7200 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Rising food prices could force 64 million Asians into extreme poverty and damage the region's economic growth this year, according to a report released on Tuesday from the Asian Development Bank, Agence France-Presse reports.
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Mindfulness meditation is an increasingly popular treatment for anxiety, but testing its effectiveness in a convincing way has been difficult. Now a rigorously designed, NIH-sponsored clinical trial has found objective physiological evidence that mindfulness meditation combats anxiety.
› Verified 3 days ago
Candace L Clawson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-1624 Fax: 907-729-1634 | |
Dr. William Murray Buttner, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-9229 Fax: 907-561-4806 | |
Robert L Mcalister, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 E 36th Ave, Anchorage, AK 99508 Phone: 907-562-2992 | |
Shane W Cummings, M D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1310 E Dimond Blvd, Suite 1, Anchorage, AK 99515 Phone: 907-344-2400 Fax: 907-344-2404 | |
Jeremy D Wood, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 Compassion Cir, Anchorage, AK 99504 Phone: 907-212-9200 Fax: 907-212-9283 | |
Kelton Hillard Oliver, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12302 Woodward Dr, Anchorage, AK 99516 Phone: 907-580-0002 | |
Ryan T. Mcwilliams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4320 Diplomacy Dr, Suite 1191, Anchorage, AK 99508 Phone: 907-729-6321 |